Outcomes of I-125 Low-Dose-Rate Brachytherapy in Patients with Localized Prostate Cancer: A Comprehensive Analysis from a Specialized Tertiary Referral Center
Journal of Personalized Medicine · 21.08.2024 · 14 (8) · 882
DOI: 10.3390/jpm14080882 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 21.08.2024. Verfasst von Philipp Schubert und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Low-dose-rate (LDR) brachytherapy with I-125 seeds is one of the most common primary tumor treatments for low-risk and low-intermediate-risk prostate cancer. This report aimed to present an analysis of single-institution long-term results. We analyzed the treatment outcomes of 119 patients with low- and intermediate-risk prostate cancer treated with LDR brachytherapy at our institution between 2014 and 2020. The analysis focused on biochemical recurrence rates (BRFS), overall survival (OS), cumulative local recurrence rate (CLRR), and the incidence of acute and late toxicities. Patient-reported quality of life measures were also evaluated to provide a holistic view on the treatment’s impact. The median follow-up period was 46 months. CLRR was 3.3% (4/119), five-year BRFS was 87%, and the five-year OS rate was 95%. Dysuria was the most common acute urinary toxicity, reported in 26.0% of patients as grade 1 and 13.4% as grade 2. As a late side effect, 12.6% of patients experienced mild dysuria. Sexual dysfunction persisted in 6.7% of patients as grade 1, 7.5% as grade 2, and 10.0% as grade 3. LDR brachytherapy in patients with prostate cancer is an effective treatment, with favorable clinical outcomes and manageable toxicity. The low CLRR and high OS rates, as well as low incidence of severe side effects, support the continued use of LDR brachytherapy as a primary treatment modality for localized prostate cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
- CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany.
- BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany.
ORCID-Profile: Philipp Schubert, Claudia Schweizer, Florian Putz
Zitieren
APA
Schubert, P., Strnad, V., Höfler, D., Schweizer, C., Putz, F., Lotter, M., Kreppner, S., Karius, A., Fietkau, R., & Merten, R. (2024). Outcomes of I-125 Low-Dose-Rate Brachytherapy in Patients with Localized Prostate Cancer: A Comprehensive Analysis from a Specialized Tertiary Referral Center. Journal of Personalized Medicine, 14(8), 882. https://doi.org/10.3390/jpm14080882
Vancouver
Schubert P, Strnad V, Höfler D, Schweizer C, Putz F, Lotter M, et al. Outcomes of I-125 Low-Dose-Rate Brachytherapy in Patients with Localized Prostate Cancer: A Comprehensive Analysis from a Specialized Tertiary Referral Center. Journal of Personalized Medicine. 2024;14(8):882. doi:10.3390/jpm14080882
BibTeX
@article{Schubert2024,
author = {Schubert, Philipp and Strnad, Vratislav and Höfler, Daniel and Schweizer, Claudia and Putz, Florian and Lotter, Michael and Kreppner, Stephan and Karius, Andre and Fietkau, Rainer and Merten, Ricarda},
title = {Outcomes of I-125 Low-Dose-Rate Brachytherapy in Patients with Localized Prostate Cancer: A Comprehensive Analysis from a Specialized Tertiary Referral Center},
journal = {Journal of Personalized Medicine},
year = {2024},
volume = {14},
number = {8},
pages = {882},
doi = {10.3390/jpm14080882}
}
EUVIMED